William Blair Predicts MaxCyte's Q1 Earnings (NASDAQ:MXCT)

MaxCyte, Inc. (NASDAQ:MXCT - Free Report) - Analysts at William Blair issued their Q1 2025 earnings estimates for MaxCyte in a report released on Wednesday, March 12th. William Blair analyst M. Larew expects that the company will earn ($0.10) per share for the quarter. The consensus estimate for MaxCyte's current full-year earnings is ($0.42) per share. William Blair also issued estimates for MaxCyte's Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.34) EPS.

MXCT has been the subject of a number of other reports. Stifel Nicolaus reduced their price target on shares of MaxCyte from $11.00 to $9.00 and set a "buy" rating for the company in a research report on Wednesday, March 12th. BTIG Research set a $6.00 price target on shares of MaxCyte and gave the stock a "buy" rating in a research report on Wednesday, March 12th.

MaxCyte Stock Performance

Shares of NASDAQ MXCT traded down $0.07 during mid-day trading on Friday, reaching $3.19. The company had a trading volume of 584,987 shares, compared to its average volume of 508,715. The stock has a fifty day moving average of $4.15 and a two-hundred day moving average of $3.96. The company has a market capitalization of $338.23 million, a price-to-earnings ratio of -9.38 and a beta of 1.35. MaxCyte has a 12-month low of $2.76 and a 12-month high of $5.26.

Hedge Funds Weigh In On MaxCyte

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MXCT. Mirabella Financial Services LLP bought a new position in MaxCyte during the fourth quarter valued at approximately $15,392,000. River Global Investors LLP raised its position in shares of MaxCyte by 57.7% in the fourth quarter. River Global Investors LLP now owns 3,253,192 shares of the company's stock valued at $13,494,000 after purchasing an additional 1,190,630 shares during the period. Cadian Capital Management LP raised its position in shares of MaxCyte by 14.1% in the fourth quarter. Cadian Capital Management LP now owns 9,344,424 shares of the company's stock valued at $38,873,000 after purchasing an additional 1,155,476 shares during the period. AXA S.A. bought a new position in shares of MaxCyte in the fourth quarter valued at approximately $4,105,000. Finally, Royce & Associates LP raised its position in shares of MaxCyte by 146.9% in the fourth quarter. Royce & Associates LP now owns 799,873 shares of the company's stock valued at $3,327,000 after purchasing an additional 475,949 shares during the period. Institutional investors own 68.81% of the company's stock.

Remove Ads

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.